Industry analysts are bullish about the financial potential of the psychedelic drug market, predicting North American sales of almost $7 billion by 2027. A continuing search for new and effective treatments for burgeoning mental illnesses fuels the confidence. On the other hand, new medicinal drugs can face more regulatory roadblocks than recreational ones. This panel, representing some of the most active companies in psychedelic research and development, will come up with a realistic timetable for the full greenlight for licensed psychoactive healing.
Moderator – Katie Pringle
